Fraser Symmans

4.2k total citations · 1 hit paper
21 papers, 1.2k citations indexed

About

Fraser Symmans is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Fraser Symmans has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in Fraser Symmans's work include Breast Cancer Treatment Studies (8 papers), DNA Repair Mechanisms (3 papers) and Cancer Treatment and Pharmacology (3 papers). Fraser Symmans is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), DNA Repair Mechanisms (3 papers) and Cancer Treatment and Pharmacology (3 papers). Fraser Symmans collaborates with scholars based in United States, France and United Kingdom. Fraser Symmans's co-authors include Carl A. Olsson, Mitchell C. Benson, Kathleen O’Toole, Marc Colombel, Ralph Buttyan, Dominique Chopin, Stanley J. Korsmeyer, Gabriel N. Hortobágyi, Lajos Pusztai and Daniel J. Booser and has published in prestigious journals such as Cancer, Cancer Research and Clinical Cancer Research.

In The Last Decade

Fraser Symmans

21 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

1993 519 citations Marc Colombel, Fraser Symmans et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fraser Symmans United States	14	597	596	317	290	124	21	1.2k
Shazli N. Malik United States	13	411 0.7×	801 1.3×	400 1.3×	232 0.8×	147 1.2×	16	1.2k
Chung-Tsen Hsueh United States	19	556 0.9×	416 0.7×	305 1.0×	200 0.7×	93 0.8×	55	1.2k
Mariko Mihara Japan	21	674 1.1×	745 1.3×	203 0.6×	230 0.8×	60 0.5×	38	1.3k
Marta Castiglia Italy	22	619 1.0×	730 1.2×	518 1.6×	608 2.1×	134 1.1×	52	1.5k
Chris Womack United Kingdom	16	594 1.0×	595 1.0×	282 0.9×	205 0.7×	98 0.8×	34	1.2k
Michio Sugita Japan	12	561 0.9×	810 1.4×	358 1.1×	389 1.3×	115 0.9×	32	1.3k
A. Craig Lockhart United States	17	477 0.8×	522 0.9×	261 0.8×	234 0.8×	87 0.7×	49	1.0k
Runsen Jin China	19	410 0.7×	520 0.9×	456 1.4×	259 0.9×	104 0.8×	54	1.1k
Ken Suzawa Japan	19	504 0.8×	483 0.8×	565 1.8×	282 1.0×	112 0.9×	80	1.1k
Vijay Peddareddigari United States	11	600 1.0×	714 1.2×	183 0.6×	170 0.6×	127 1.0×	18	1.2k

Countries citing papers authored by Fraser Symmans

Since Specialization

Citations

This map shows the geographic impact of Fraser Symmans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fraser Symmans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fraser Symmans more than expected).

Fields of papers citing papers by Fraser Symmans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fraser Symmans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fraser Symmans. The network helps show where Fraser Symmans may publish in the future.

Co-authorship network of co-authors of Fraser Symmans

This figure shows the co-authorship network connecting the top 25 collaborators of Fraser Symmans. A scholar is included among the top collaborators of Fraser Symmans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fraser Symmans. Fraser Symmans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garber, Haven R., Gaiane M. Rauch, Beatriz E. Adrada, et al.. (2020). Abstract P2-16-09: Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). Cancer Research. 80(4_Supplement). P2–16. 2 indexed citations

Wulfkuhle, Julia, Christina Yau, Denise M. Wolf, et al.. (2018). Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. JCO Precision Oncology. 2(2). 1–20. 33 indexed citations

Criscitiello, Carmen, Mohamed Amine Bayar, Giuseppe Curigliano, et al.. (2017). A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Annals of Oncology. 29(1). 162–169. 45 indexed citations

Meric‐Bernstam, Funda, Kurt W. Evans, Xiaofeng Zheng, et al.. (2017). Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy. Cancer Research. 77(13_Supplement). 4970–4970. 1 indexed citations

Wolf, Denise M., Christina Yau, Ashish Sanil, et al.. (2016). Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL. Cancer Research. 76(14_Supplement). 858–858. 2 indexed citations

Wolf, Denise M., Christina Yau, Lamorna Brown Swigart, et al.. (2016). Abstract 859: Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer. Cancer Research. 76(14_Supplement). 859–859. 5 indexed citations

Wolf, Denise M., Christina Yau, Ashish Sanil, et al.. (2015). Abstract P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research. 75(9_Supplement). P3–6. 2 indexed citations

Bayraktar, Soley, Angelica M. Gutierrez‐Barrera, Lajos Pusztai, et al.. (2013). USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. The Cancer Journal. 19(1). 10–17. 38 indexed citations

Niikura, Naoki, Bruno C. Odisio, Yutaka Tokuda, et al.. (2013). Latest biopsy approach for suspected metastases in patients with breast cancer. Nature Reviews Clinical Oncology. 10(12). 711–719. 17 indexed citations

10.

Holder, Ashley M., Ana M. González-Angulo, Huiqin Chen, et al.. (2012). Abstract 682: Increased stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Cancer Research. 72(8_Supplement). 682–682. 2 indexed citations

11.

Lü, Jing, Ming Tan, Wen-Chien Huang, et al.. (2009). Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance. Clinical Cancer Research. 15(4). 1326–1334. 65 indexed citations

12.

Khalifeh, Ibrahim, Constance T. Albarracin, Leslie K. Diaz, et al.. (2008). Clinical, Histopathologic, and Immunohistochemical Features of Microglandular Adenosis and Transition Into In Situ and Invasive Carcinoma. The American Journal of Surgical Pathology. 32(4). 544–552. 69 indexed citations

13.

Kawase, Kazumi, Isis Gayed, Kelly K. Hunt, et al.. (2006). Use of Lymphoscintigraphy Defines Lymphatic Drainage Patterns Before Sentinel Lymph Node Biopsy for Breast Cancer. Journal of the American College of Surgeons. 203(1). 64–72. 30 indexed citations

14.

Pusztai, Lajos, Peter J. Wagner, Nuhad K. Ibrahim, et al.. (2005). Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma. Cancer. 104(4). 682–691. 238 indexed citations

15.

Pusztai, Lajos, Fraser Symmans, & Gabriel N. Hortobágyi. (2005). Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer. 12(2). 73–85. 15 indexed citations

16.

Symmans, Fraser. (2001). Breast cancer response to paclitaxel in vivo. Drug Resistance Updates. 4(5). 297–302. 19 indexed citations

17.

Symmans, Fraser, Joan Cangiarella, Jean-Marc Cohen, et al.. (2000). Apoptotic Index from Fine Needle Aspiration Cytology as a Criterion To Predict Histologic Grade of Non-Hodgkin’s Lymphoma. Acta Cytologica. 44(2). 194–204. 5 indexed citations

18.

Dodd, Leslie G., Douglas B. Evans, Fraser Symmans, & Ruth L. Katz. (1994). Fine‐needle aspiration of pancreatic extramedullary plasmacytoma: Possible confusion with islet cell tumor. Diagnostic Cytopathology. 10(4). 371–374. 16 indexed citations

19.

Colombel, Marc, Fraser Symmans, Kathleen O’Toole, et al.. (1993). Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.. PubMed. 143(2). 390–400. 519 indexed citations breakdown →

20.

Symmans, Fraser, et al.. (1992). Correlation of Cervical Cytology and Human Papillomavirus DNA Detection in Postmenopausal Women. International Journal of Gynecological Pathology. 11(3). 204–209. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact